- Report
- July 2023
- 108 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- February 2024
- 111 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- November 2021
- 802 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- November 2021
- 1184 Pages
Global
From €5726EUR$6,000USD£4,798GBP
- Report
- December 2021
- 123 Pages
Global
From €3543EUR$3,712USD£2,968GBP
- Report
- July 2024
- 280 Pages
Global
From €2534EUR$2,655USD£2,123GBP
- Report
- October 2022
- 258 Pages
Global
From €3407EUR$3,570USD£2,855GBP
- Book
- January 2015
- 464 Pages
- Book
- March 2022
- 896 Pages
- Book
- August 2018
- 352 Pages
DNA vaccines are a type of genomics-based vaccine that uses genetic material from a virus or bacteria to stimulate an immune response. They are created by introducing a gene that codes for a specific antigen into a plasmid, which is then inserted into a host cell. The host cell then produces the antigen, which is then used to stimulate an immune response. DNA vaccines are considered to be safer than traditional vaccines, as they do not contain any live virus or bacteria. Additionally, they can be produced more quickly and cheaply than traditional vaccines.
DNA vaccines have been used to treat a variety of diseases, including influenza, malaria, and HIV. They have also been used to develop vaccines for cancer and other diseases. Recently, DNA vaccines have been used to develop vaccines for the prevention of infectious diseases, such as Zika virus and Ebola.
Companies in the DNA Vaccines market include Moderna, Inovio Pharmaceuticals, Novavax, and Transgene. Show Less Read more